CAR-T免疫细胞疗法在抗病毒感染中的研究进展

Research progress in CAR-T immunotherapy for antiviral infections

目前,世界上大多数病毒感染没有针对性的特效药,尤其是具有潜伏感染能力的病毒,如乙型肝炎病毒(hepatitis B virus,HBV)、巨细胞病毒(cytomegalovirus,CMV)、Epstein-Barr病毒(epstein-barr virus,EBV)、人类免疫缺陷病毒(human immunodeficiency virus,HIV)等,严重威胁人类健康。这些病毒感染宿主细胞后,与宿主蛋白互作,导致宿主细胞在其表面表达一些特异性的感染或潜伏标志蛋白,可以成为CAR-T细胞疗法(chimeric antigen receptor T-cell immunotherapy,CAR-T)的靶点,为难治性病毒性疾病的治愈提供了新的方向。

At present,most viral infections in the world have no miracle drugs,especially viruses with latent infection ability,such as hepatitis B virus(HBV),cytomegalovirus(CMV),Epstein-Barr virus(EBV),human immunodeficiency virus(HIV),etc.,which seriously threaten human health.After infecting host cells,these viruses interact with host proteins,causing host cells to express some specific infectious or latent marker proteins on cell surface,which can become targets of CAR-T therapy,providing a new direction for the cure of refractory viral diseases.